Bristol Myers Squibb and BioNTech Announce $11.1 Billion Global Collaboration to Co-Develop and Co-Commercialize BNT327, a Next-Generation PD-L1/VEGF-A Bispecific Antibody for Solid Tumors

2025Year6Month2Day,BioNTech SE(NASDAQ Code:BNTX, hereinafter referred to as“BioNTech”) andBristol Myers Squibb(New York Stock Exchange code:BMY, hereinafter referred to as“BMS”) Announced a global strategic cooperation agreement to jointly develop and commercializeBioNTechThe Next Generation Bispecific AntibodyBNT327, this drug is expected to be used for the treatment of various solid tumors.

Screenshot source: BMS official website

BNT327: Innovative bispecific antibody

BNT327YesBioNTechA novel bispecific antibody developed that can simultaneously targetPD-L1AndVEGF-ATwo validated tumor treatment targets. ByPD-L1Immune Checkpoint Inhibition andVEGF-ANeutralization and binding in one molecule,BNT327Aiming to RestoreTThe ability to recognize and destroy tumor cells, while reversing the immunosuppressive effects in the tumor microenvironment and cutting off the blood and oxygen supply to tumor cells (anti-angiogenic effect), thereby halting tumor growth and spread.

Cooperation Details

According to the cooperation agreement,BioNTechAndBMSWill Co-Develop and CommercializeBNT327, including its use as a monotherapy and in combination with other products. Both parties will jointly bear the development and manufacturing costs, and equally share profits and losses on a global scale.

BMSWill be submitted toBioNTechPayment15Hundreds of millions of dollars in upfront payments, and up to2028Total by year20Hundreds of millions of dollars in non-contingent anniversary payments. In addition,BioNTechAlso eligible for up to76Hundreds of millions of dollars in additional development, regulatory, and commercial milestone payments.BioNTechAndBMSWill be implemented according to50:50The proportion of jointly bearing the joint development and manufacturing costs, and evenly distributing profits and losses worldwide.

Clinical Development Plan

BNT327Currently, multiple clinical trials are underway, with more than1000Patients received treatment. Ongoing global3The trial period includes evaluationBNT327As extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC) First-line treatment trials. In addition, plans are in place for2025To be launched by the end of the year for triple-negative breast cancer (TNBC) Global3Phase Trial.

This collaboration marksBioNTechAndBMSThe strong collaboration in the field of immuno-oncology is expected to bring new treatment options and hope to patients with various solid tumors.BNT327The development and commercialization process will be closely watched by the global medical community.